Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Brian Sworder

Has grant

Assistant Professor

City Of Hope National Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Recent Grants

Grant: Close

Molecular characterization of tumor intrinsic mechanisms of resistance to CAR T-cell therapy

Open Date: 2021-04-01

Close Date: 2023-10-31

Articles (17)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (11)

Jason R. Westin

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

David B Miklos

Stanford University

UNITED STATES

View details

University of Washington

UNITED STATES

View details

Mark Roschewski

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Brian Sworder

Research Interests

Explore related searches

Recent Grants

Articles (17)

A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma

Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.

Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma.

Prognostic value of circulating tumor DNA (ctDNA) detection by PhasED-Seq after axicabtagene ciloleucel (axi-cel) therapy in relapsed/refractory large B-cell lymphoma (LBCL).

IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies

Abstract 3252: Circulating tumor DNA (ctDNA) enables enhanced measurable residual disease (MRD) detection and non-invasive clonal profiling in acute myeloid leukemia (AML)

Clonal Hematopoiesis Underlies Prolonged Cytopenias after Anti-BCMA CAR-T Therapy

Determinants of Post-CAR Myeloid Neoplasms Evolving after Lymphoma Therapy

Anatomic Genetic Heterogeneity Is Uncovered By Concurrent Cell-Free DNA and Tissue Profiling and Predicts Treatment Resistance in Diffuse Large B-Cell Lymphoma

Circulating Tumor DNA (ctDNA) Enables Superior and Universal Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) Highly Predictive of Relapse Free and Overall Survival

Dynamics of Circulating Tumor DNA As a Predictor of Outcomes with Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma from the Transcend NHL-001 Study

Non-Invasive Characterization and Early Detection of Post-Transplant Lymphoproliferative Disorders

Resolving the Microarchitecture of Classic and Transformed Follicular Lymphoma By Single Cell Alignment to Spatial Transcriptomes

Single Institution Analysis of Lymphoma Treatment Related Post-CAR Myeloid Neoplasms

Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Collaborators (11)

Jason R. Westin

David B Miklos

Michael S. Khodadoust

James Godfrey

Arash Ash Alizadeh

Joseph Schroers-Martin

Pablo Domizi

Elena Sotillo

David Kurtz

Ajay Gopal

Mark Roschewski

Make your next move.